1 / 21

Hypotensive Agents

Hypotensive Agents. R1 이송이. Hypotensive Agents. Hypotensive Agents Volatile anesthetics Sympathetic antagonists and agonists Calcium channel blockers and ACE-inhibitors Nitrates, Adenosine, Fenoldopam  dilating pph. vessels. SODIUM NITROPRUSSIDE. Mechanism of Action

baylee
Download Presentation

Hypotensive Agents

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Hypotensive Agents R1 이송이

  2. Hypotensive Agents • Hypotensive Agents • Volatile anesthetics • Sympathetic antagonists and agonists • Calcium channel blockers and ACE-inhibitors • Nitrates, Adenosine, Fenoldopam  dilating pph. vessels

  3. SODIUM NITROPRUSSIDE • Mechanism of Action • Relax both arteriolar and venous smooth muscle • Its primary mechanism of action is shared with other nitrates (eg. hydalazine and nitroglycerine)  Release of nitric oxide  activate guanylyl cyclase  synthesis of cGMP  smooth m. contraction

  4. SODIUM NITROPRUSSIDE • Nitric oxide • Potent vasodilater released by endothelial cells (endothelium-derived relaxing factor) • Inhaled nitric oxide • Selective pulmonary vasodilator : beneficial in the treatment of reversible pulmonary HTN • Improves oxygenation in ARDS pts or during one-lung ventilation • Anti-inflammatory effect

  5. SODIUM NITROPRUSSIDE • Clinical Uses • Potent & reliable antihypertensive • Diluted to 100μg/ml • Continuous IV infusion : 0.5-10 μg/kg/min • Extremely rapid onset : 1-2 min • Bolus (1-2 μg/kg) : minimizes BP elevation during laryngoscopy, but can cause transient Hypotension • Requires frequent BP monitoring (intraarterial monitoring)

  6. SODIUM NITROPRUSSIDE • Metabolism • Sodium nitroprusside(SNP) enters red blood cells  receives Fe 2+ from oxyhemoglobin  results in an unstable nitroprusside radical(SNP‾) and methemoglobin(Hgb Fe 3+) • SNP‾ decomposes in to5cyanide ions and the active nitroso group • Cyanide ions (1)bind to methemoglobin  cyanmethemoglobin (2)bind to thisulfate  thiocyanate (3)bind to tissue cytochrome oxidase cyanide toxicity

  7. SODIUM NITROPRUSSIDE • Acute cyanide toxicity • Metabolic acidosis, cardiac arrhythmia, increased venous oxygen contents • Can be avoided if the cumulative dose is less than 0.5mg/kg/h • Treatment : mechanical ventilation with 100% oxygen, sodium thiosulfate(150mg/kg over 15 min), 3% sodium nitrate(5mg/kg over 5min)

  8. SODIUM NITROPRUSSIDE <Effects on organ systems> • Cardiovascular • Dilation of venous and arterial beds  ↓ preload & afterload • ↓ pph. vascular resistance  ↓ ABP • ↓ preload  ↓ myocardia work, ↓ risk of ischemia • Cerebral • cerebral vessels dilation & abolish autoregulation • cerebral blood flow is maintained or increased • Pts with decreased intracranial compliance (eg. brain tumor)  increaseintracranial pr.

  9. SODIUM NITROPRUSSIDE <Effects on organ systems> • Respiratory • Pul. vasculature dilatation • ↓ pul. artery pr. ↓ perfusion  ↑ physiological dead space • Prevent pul. vasoconstrictive response to hypoxia • Mismatch pul. Ventilation toperfusion & decrease arterial oxygenation • Renal • ↓ ABP  rennin & catecholamine release • Can cause pressure rebound after discontinuation • Renal function is fairly well maintained

  10. SODIUM NITROPRUSSIDE • Drug Interactions • Does not directly interact with NM blocking agent • ↓ muscle blood flow indirectly prolong NM blockade

  11. NITROGLYCERIN • Mechanism of action • Relax vascular smooth m. • venous dilation predominating over arterial dilation • Clinical uses • Diluted to 100μg/ml • Continuous Infusion : 0.5-10 μg/kg/min • Sublingual (peak effect 4min) • Transdermal

  12. NITROGLYCERIN • Metabolism • reductive hydrolysis in liver and blood by glutathione-organic nitrates reductase <Effects on organ systems> • Cardiovascular • ↓ venous return&preload • ↓ afterload d/t arteriolar dilation • ↓ end-systolic pr. & O2 demand • Redistribution of coronary blood flow ischemic areas of subendocardium • Relief of coronary artery spasm • ↓ platelet aggregation & ↑coronary vesselpotency

  13. NITROGLYCERIN <Effects on organ systems> • Cerebral • Similar to sodium nitroprusside • side effect :headache (cerebral vessel dilation) • Respiratory • bronchial smooth musclerelaxation

  14. HYDRALAZINE • Mechanism of Action • Arteriolar smooth muscle relaxation • Clinical Use • Control of intraoperative HTN : IV 5-20mg (onset within15 min, duration 2-4 hr) • Continuous infusion is less frequently used d/t their slow onset and long duration

  15. HYDRALAZINE <Effects on organ systems> • Cardiovascular • ↓ pph. vascular resistance  ↓ arterial BP • ↑ HR, myocardial contractility, CO • Cerebral • Potent cerebral vasodilator & inhibit cerebral blood flow autoregulation • Renal • Renal blood flow is maintained or increased

  16. ADENOSINE • Mechanism of Action • Acts on specific adenosine Rc located in several vascular beds and on theAV node • Activates adenylate cyclase and Depresses action potential • Slows sinus rates in PSVT pts.

  17. ADENOSINE • Clinical Uses • Potent vasodilator during anesthesia • Affects arteriolar reistance vessels(afterload) without affecting venous capacitance(preload) • Very short half-life : <10 seconds • Continuous Infusion : 60-120μg/kg/min • Tx of PSVT &WPW synd.: IV bolus 6mg  can cause atrial fibrillation

  18. ADENOSINE <Effects on organ systems> • Cardiovascular • ↓ systemic vascular resistance  ↓ ABP • ↑ cardiac index, HR, stroke vol. • ↑ myocardial blood flow • ↓ A-V conduction  inhibitreentrant arrhythmias • Pulmonary • ↓ pul. vascular resistance↑ intrapulmonary shunt  ↓ arterial oxygen saturation • Renal • Renal vasoconstriction  renal blood flow를 떨어뜨림

  19. FENOLDOPAM • Mechanism of Action • Rapid vasodilation • Clinical Uses • ↓ systolic and diastolic blood pr. • side effect : headache, flushing, nausea, tachycardia, hypokalemia, HTN • Onset within 15 min • No rebound HTN

  20. FENOLDOPAM <Effects on organ systems> • Cardiovascular • ↓ systolic and diastolic pr. • ↑ HR • Ophthalmic • ↑ Intraocular pr. • Caution in glaucoma pts and ↑intraocular pr. • Renal • ↑ Renal blood flow • ↓ ABP but GFR is maintained • Compared to sodium nitroprusside • ↑ urinary flow rate, ↑ urinary sodium extraction, ↑ creatinine clearance

  21. FENOLDOPAM • Warnings • allergic reaction : high risk in pts with a Hx of asthma or sulfite sensitivity history

More Related